n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, February 16th, 2016

The QualityStocks
Daily Stock List

graphic
graphic

Premier Holding Corp. (PRHL)

SmallCapVoice, The Green Baron, and Clutch Investments reported earlier on Premier Holding Corp. (PRHL), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Premier Holding Corp. is an energy holding company concentrating on acquiring and integrating energy companies as synergistic subsidiaries. Premier accumulates residential and commercial clients in deregulated markets from all subsidiaries and cross sells energy and energy efficiency products and services, maximizing profit potential and minimizing cost of client procurement. Premier Holding has its headquarters in Tustin, California.

Additionally, the Company provides top line management and financial support. This includes access to capital, financing, legal, insurance, mergers, acquisitions, joint ventures (JVs) and management strategies. Additional integrated business offerings include direct energy services as power purchase agreements (PPAs), energy financing and leasing of generation programs in urban and rural real estate environments, lighting efficiency systems and refrigeration systems.

Premier Holding, by way of its subsidiaries, provides renewable energy production, energy efficiency products and services to commercial middle-market companies, Fortune 500 brands, developers, and management companies of large-scale residential developments. Its companies lessen its customers’ price and usage of energy. Its subsidiary, The Power Company (TPC), via deregulated energy expertise, has helped tens of thousands of customers.

Through its energy efficiency company, E3 - Energy Efficiency Experts, Premier allows for continuing support through energy management and information systems. E3 is an Energy Services Company (ESCO) and distributor created by Premier Holding to provide the best of breed solutions to its clients through recruiting experts with decades of experience in the field, and by employing proprietary technologies and high level industry relationships.

Premier Holding continues to explore opportunities to become a supplier through application or acquisition/merger with an existing supplier to fulfill its plans for growth. Upon completion, the new subsidiary will be a power provider/supplier licensed with the Public Utility Commissions. This subsidiary will enable Premier to leverage the marketing success of energy brokers such as The Power Company and ultimately create new energy efficiency prospects for E3, enabling Premier to further its plan of integration in this sector.

This month, Premier Holding announced that it is proud of the performance of its subsidiary, Energy Efficiency Experts (E3), for the notable performance it attained on a recent project for Men's Fashion Depot in San Diego, California. After over three months of waiting for another LED vendor to finish the job, Men's Fashion Depot contacted Energy Efficiency Experts (E3) to complete the job.

Within five days of the call, E3 had completed the installation of a project, which included replacing 468 fluorescent and other lamps consuming 187,308 KWh annually with LED lamps. E3 audited, specified, and managed the project whereby it replaced these old lamps with 468 LED lamps consuming only 86,835 KWh annually. That is more than 53 percent savings in power consumption.

Premier Holding Corp. (PRHL), closed Tuesday's trading session at $0.072, up 10.77%, on 62,700 volume with 15 trades. The average volume for the last 60 days is 51,267 and the stock's 52-week low/high is $0.022/$0.0988.

MRI Interventions, Inc. (MRIC)

Wall Street Resources, Real Pennies, and FeedBlitz reported on MRI Interventions, Inc. (MRIC), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

MRI Interventions, Inc. is a medical device company that develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Utilizing a hospital's existing MRI suite, the design of its Food and Drug Administration (FDA)-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. MRI Interventions has its corporate headquarters in Irvine, California.

The Company has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint® system. ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software. The ClearPoint® system enables real-time MRI-guided navigation for a broad array of minimally-invasive neurosurgery procedures. The platform is particularly well-matched for facilitating drug delivery directly to brain tumors.

The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.

The ClearPoint® system is the only navigation platform designed to allow real-time visualization during minimally-invasive neurosurgical procedures. ClearPoint software works with MRI to assist surgeons in planning a target and trajectory. The SmartFrame® targeting devices enable the MRI-guided alignment and minimally invasive insertion of surgical instruments.

Furthermore, MRI Interventions is developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. In addition, the Company is working with Boston Scientific to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications.

This month, MRI Interventions announced that its ClearPoint Neuro Navigation System was used for its 1,000th neurosurgical procedure. Since receiving 510(k) clearance from the FDA in 2010, the ClearPoint system has been used by over 40 leading institutions across the nation.

Mr. Frank Grillo, MRI Interventions’ President and Chief Executive Officer, stated, “More than one thousand patients have now benefited from the sub-millimeter accuracy and real-time, MRI-based visualization enabled by our ClearPoint Neuro Navigation System during brain surgeries such as electrode insertion, biopsies and catheter placement.”

MRI Interventions, Inc. (MRIC), closed Tuesday's trading session at $0.3149, up 7.11%, on 61,361 volume with 25 trades. The average volume for the last 60 days is 77,379 and the stock's 52-week low/high is $0.2601/$1.46.

Premier Biomedical, Inc. (BIEI)

PennyStockRumors.net, The Observer, PennyPro, Innovative Marketing, SmallCapVoice, PennyStocks24, Information Solutions Group, and FeedBlitz reported earlier on Premier Biomedical, Inc. (BIEI), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Premier Biomedical, Inc. is a research-based medical development company. Its goal is to discover and develop medical treatments, in collaboration with the University of Texas at El Paso (UTEP) and the US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier Biomedical has its headquarters in El Paso, Texas.

Premier has licensed the technology behind many provisional patents in the U.S. and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. The Company has developed a determined timetable to further the development of these technologies through the laboratory, hospital, as well as clinical trials. It has started the development of potential patient trial application lists.

It is initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier Biomedical announced in June 2014 that the United States Patent Office approved a patent on its proprietary medication Feldetrex ™. The design of this medication is to relieve the symptoms of neuropathic pain and fibromyalgia.

The Company has been evaluating strategies to take its own Anti-CTLA4 breast cancer treatment through the Food and Drug Administration (FDA) approval process.
Premier has several other continuing projects, in addition to its Anti-CTLA-4-based breast cancer drug. In two upcoming clinical trials, its plan is to test its Feldetrex™ pain medication, followed by a separate clinical trial of its core technology designed to remove the pathophysiological basis of the disease.

Premier Biomedical signed a Patent License Agreement with UTEP, covering the cancer treatment process called "CD152-LDMC", which the two entities have been developing in cooperation at the Border Biomedical Research Center, located in UTEP's $45-million Bioscience Research Building. The proprietary process strives to block a molecule called cytotoxic T-lymphocyte antigen or CTLA-4, through combining CTLA-4 blocking antibody CD152, along with Low Dose Metronomic Chemotherapy. Important progress has been made advancing the development of CD152-LDMC.

Today, Premier Biomedical announced that it believes its recently patented (U.S. Pat. #9,216,386) treatment methodology, in combination with pending provisional patent applications, can be effectively used in treating Zika, and Dengue, and also other serious viruses. The Company, jointly with its Brazilian JV partner, Auramedi, is working to hasten its research efforts in this area.

Premier Biomedical, Inc. (BIEI), closed Tuesday's trading session at $0.0215, up 20.11%, on 786,324 volume with 44 trades. The average volume for the last 60 days is 5,590,151 and the stock's 52-week low/high is $0.0023/$0.16.

PetLife Pharmaceuticals, Inc. (PTLF)

TopPennyStockMovers, PHUB News, DSR News, SixFigureStockPicks, Winning Penny Stock Picks, Penny Stock Circle, 1-2-3 Stock Alerts, StockMister, Fortune Stock Alerts, RisingPennyStocks, Super Hot Penny Stocks, PennyStockMoneyTrain, WePickPennyStocks, Liquid Tycoon, Penny Stock Pick Alert, Penny Stock Pick Report, PennyPickAlerts, Super Nova Stock Picks, Joe Penny Stocks, FOX Penny Stocks, Wall St Report, smartOTC, and OTC Markets Group reported previously on PetLife Pharmaceuticals, Inc. (PTLF), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Incorporated in 2012, PetLife Pharmaceuticals, Inc. is a developer of new generation high potency veterinary cancer medications and nutraceuticals for pets. PetLife is a registered US Veterinary Pharmaceutical company. The Company is a spinoff of Medolife Corp. The Company previously went by the name PetLife Corp. It changed its name to PetLife Pharmaceuticals, Inc. in August of 2014.  PetLife Pharmaceuticals is headquartered in Beverly Hills, California.

The Company’s management team consists of experts and professionals in the veterinary, business, sales and management fields. PetLife Pharmaceuticals’ Founder, Chief Executive Officer (CEO) and President is Mr. Arthur G. Mikaelian, Ph.D. Dr. Mikaelian, for the past two decades, has been independently, actively studying stress hormones (cortisol, epinephrine), master gene (ATF3) and their indirect influences on cancer cell activity and tumor progression.

PetLife’s primary goal is to develop a new generation of scientifically proven, potentiated bioactive medications and nutraceuticals and bring them to the world of veterinary oncology. The marketing and selling of the products is under the name Escozine For Pets™.

The Escozine for Pets™ GNP-1 drug version is Escozine for Pets™ combined with gold nanoparticles that will enhance the effectiveness and increase the targeting capability of the product. The Escozine for Pets™ – nutraceutical (natural) version will be the first product to be marketed and sold.

The polarized main ingredients in PetLife Pharmaceuticals’ products have been demonstrated as a preventative and a treatment of cancer to improve quality and extend longevity of life, as an alternative to conventional chemotherapy. 

Escozine for Pets™ is based on the same patented 'Escozine for humans' formula, which has been sold by affiliate Medolife in 40 countries, using a patented polarization technology, which potentiates the principal ingredients to appreciably increase their effectiveness. The innovative feature of the Company’s nutraceutical, Escozine for Pets™, is that it is produced with a patented process, which strengthens and potentiates the function of its active ingredients to substantially support overall health and greatly restore normal cellular functions.

PetLife Pharmaceuticals, Inc. (PTLF), closed Tuesday's trading session at $0.04, up 25.00%, on 20,900 volume with 3 trades. The average volume for the last 60 days is 5,662 and the stock's 52-week low/high is $0.015/$0.275.

Galaxy Gaming, Inc. (GLXZ)

RedChip, SmallCapVoice, TaglichBrothers, The Green Baron, FeedBlitz, and Stock Profile reported on Galaxy Gaming, Inc. (GLXZ), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Galaxy Gaming, Inc. is the world's second largest manufacturer and provider of casino table games and enhanced gaming systems. The Company develops, manufactures, and distributes innovative proprietary table games, state-of-the-art electronic wagering platforms, and also enhanced bonusing systems to land-based, riverboat, cruise ships, and online casinos around the world. The Company’s games can be played online at FeelTheRush.com. Galaxy Gaming has its corporate head office in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

By way of the Company’s iGaming partner, Games Marketing Ltd., Galaxy Gaming licenses its proprietary table games to the online gaming industry. Moreover, it is expanding its international presence through its partnership with WPT Enterprises, Inc. WPT Enterprises is the owner of the World Poker Tour. In addition, Galaxy Gaming is the exclusive provider of SpectrumVision. This is a proprietary technology used to detect invisible markings on playing cards.

Presently, Galaxy Gaming has an installed base of its products on greater than 4,000 gaming tables located in over 500 casinos. Galaxy Gaming sells its products primarily through its internal sales force, to casinos across North America, the Caribbean, the British Isles, Europe, and Africa and to cruise ships and internet gaming sites globally.

Galaxy Gaming announced in 2015 that the Kansas Racing and Gaming Commission issued to the Company its Gaming Supplier Certificate at its regularly scheduled meeting held in Topeka, Kansas.

Last month, Galaxy Gaming announced that the Pennsylvania Gaming Control Board granted certification to Galaxy Gaming as a Gaming Related Gaming Service Provider at its regularly scheduled meeting held on January 13, 2016 in Harrisburg, Pennsylvania.  The Gaming Control Board’s action provides Galaxy Gaming with permanent certification to offer its products to casinos statewide.

The Company, in addition to Pennsylvania, is approved to conduct its gaming business in roughly 100 gaming jurisdictions in the United States and internationally.

Galaxy Gaming, Inc. (GLXZ), closed Tuesday's trading session at $0.175, up 25.00%, on 5,020 volume with 3 trades. The average volume for the last 60 days is 2,268 and the stock's 52-week low/high is $0.12/$0.3699.

graphic

The QualityStocks
Company Corner

graphic
graphic

OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.89, up 10.56%, on 1,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 3,875, and its 52-week low/high is $0.45/$1.00.

OurPet's Company plans to unveil a new, first-of-its-kind line of products at Global Pet Expo in Orlando, Florida, March 16-18, 2016. The Global Pet Expo is the industry's largest trade show featuring the newest, most innovative products in the marketplace. Last year's show featured 1,051 exhibitors, 3,113 booths, and more than 3,000 new product launches.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

OurPet's (OPCO) Expects New Product Line to Make Big Splash at Global Pet Expo

OurPet's Commits to Further Innovation in Pet Products That Enhance Pet/Owner Relationship

Dean Tsengas Named Chief Operations Officer of OurPet's Company

Dominovas Energy Corp. (DNRG)

The QualityStocks Daily Newsletter would like to spotlight Dominovas Energy Corp. (DNRG). Today, Dominovas Energy Corp. closed trading at $0.0245, up 8.89%, on 4,258,308 volume with 180 trades. The stock’s average daily volume over the past 60 days is 1,287,754 and its 52-week low/high is $0.0035/$0.40.

Dominovas Energy Corp. announces an agreement of principal terms to acquire Grupo Trébol Holding, based in Guatemala City, Guatemala. Grupo Trébol is a private global energy solutions company with operations and strategic partnerships throughout Central and South America.

Dominovas Energy Corp. (DNRG) is an energy solutions company dedicated to bringing clean, sensible and reliable power to areas of the world that lack this precious commodity. Recognizing the incredible growth and profit opportunities of the green and alternative energy markets, Dominovas Energy defined a sustainable deployment model to take a leading position among alternative green energy solutions providers.

At the heart of Dominovas Energy’s Fuel Cell Division is a revolutionary energy solution powered by the RUBICON™ Series Solid Oxide Fuel Cell (SOFC) Technology. Invented by inventor, scholar, professor and visionary Dr. Shamiul Islam, RUBICON™ achieves more than 50% fuel-to-electricity efficiency, providing cost effective, clean, significantly-reduced emissions with silent operations in 100kW to multi-megawatt power arrays. The proprietary system is capable of reforming and converting multiple fuel stocks, and is expected to become the “PLATINUM Standard” by which all other fuel cell technologies are measured.

In early 2014, Dominovas Energy was acquired by Western Standard Energy Corp. in a merger transaction in which Dominovas Energy was the emerging entity. Per the acquisition, Dominovas Energy obtained Western Standard’s 49.25% ownership of award-winning renewable energy company Pro Eco Energy Ltd. Pro Eco Energy provides award-winning heating and cooling systems for commercial and public buildings, delivering the newest alternative energy technologies for energy efficient HVAC systems in a timely and cost-competitive manner.

Dominovas Energy intends to build and own fuel cell utilities worldwide, joining the ranks of some of the world’s largest and most well-known companies that are already taking advantage of the vast opportunities of fuel cell systems. The RUBICON™ is far superior to any other system on the market today, and Dominovas Energy’s ability to produce a fuel cell that accepts multiple fuel sources is invaluable to meet the demands of the mass market. Disclaimer

Dominovas Energy Corp. Blog

Dominovas Energy Corp. News:

Dominovas Energy Agrees to Acquire Grupo Trebol in Guatemala City, Guatemala

Dominovas Energy Signs Financing Agreement With GHS Capital

Dr. Islam Lectures on the RUBICON Design -- The Industry's First Scalable Single Megawatt SOFC System

Nutra Pharma Corp. (NPHC)

The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.042, on 255,138 volume with 24 trades. The stock’s average daily volume over the past 60 days is 441,715, and its 52-week low/high is $0.0025/$0.27.

Nutra Pharma Corp. announced today a key expansion of personnel with the addition of Thomas W. Northrop as the Company's Senior Commercial Development Officer. Thomas W. Northrop, MHA, FACHE holds a Masters in Health Management from Duke University's Fuqua School of Business, and is a Fellow of the American College of Healthcare Executives. Mr. Northrop has led hospitals, healthcare networks, and physician groups in several regions of the country, and has worked extensively in developing new healthcare businesses.

Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.

Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.

ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer

Nutra Pharma Corp. Company Blog

Nutra Pharma Corp. News:

Nutra Pharma Announces Management Expansion and Business Updates

Nutra Pharma Corp.’s (NPHC) 7-year Marketing Exclusivity for Pediatric MS RPI-78M is more than just Luck

Nutra Pharma Letter to Shareholders

GTX Corp. (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.011, up 37.50%, on 735,326 volume with 20 trades. The stock’s average daily volume over the past 60 days is 435,987, and its 52-week low/high is $0.0052/$0.023.

GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.

GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.

The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.

As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.

"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer

GTX Corp. Company Blog

GTX Corp. News:

GTX Corp to Present at 2nd Annual Innovations Investor Conference and Announces Date of Shareholder Meeting

GPS SmartSoles Launch in Latin America

GTX Corp Engages Maxim Group LLC to Provide Strategic Advisory Services

Star Mountain Resources, Inc. (SMRS)

The QualityStocks Daily Newsletter would like to spotlight Star Mountain Resources, Inc. (SMRS). Today, Star Mountain Resources, Inc. closed trading at $0.59, up 0.17%, on 17,000 volume with 4 trades. The stock’s average daily volume over the past 60 days is 8,586, and its 52-week low/high is $0.40/$1.40.

Star Mountain Resources, Inc. (SMRS), a minerals exploration company, is focused on acquiring and consolidating mining claims, mineral leases, producing mines, and historic mines with production and future growth potential identified through exploration efforts. The company's operations are currently focused on the initiation, production and expansion of acquired mineral resources in the Star Mountain Mining District, Beaver County, Utah and turning them into producing assets.

Comprised of 2,320 acres, the company's Star Mountain/Chopar Mine project consists of 116 lode-mining claims and four metalliferous mineral lease sections located in the Star Mountain range, Star Mining District, in Beaver County, Utah, approximately five miles west of Milford, Utah. Exploration activities to date include geological analysis, and a limited reverse circulation & core drilling program.

The Star Mountain Mining District, which is dotted with historic mines dating back to the late 1800s, has a long and storied history within the mining industry. The company believes that the application of modern exploration tools will reveal additional resources that were previously unattainable. Leveraging the region's mild climate and accessibility to nearby rail lines and roads, management will look to translate this potential into sustainable returns in the years to come.

Star Mountain Resources has adopted a discovery-based business model to grow its industry presence in the future. The company plans to thoroughly explore and initially develop its leasehold before seeking senior industry partners to assist in the capital-intensive development and operation phases. Building on this strategy, Star Mountain Resources will also continue to seek quality projects that can be evaluated on their own technical and financial merit. Disclaimer

Star Mountain Resources, Inc. Company Blog

Star Mountain Resources, Inc. News:

Star Mountain Resources Receives Industry Guide 7 Mineral Reserves Report on Balmat Mine

Star Mountain Resources, Inc. Closes Acquisition of Balmat Zinc Mine in New York State

Star Mountain Resources, Inc. to Acquire Balmat Zinc Mine in New York State

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

Fortune Stock Alerts
(GOGY)

2.

MissionIR
(CNCK)

3.

HotStockProfits
(PVHO)

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251